Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : PFE (Pfizer) How high will it go? -- Ignore unavailable to you. Want to Upgrade?

To: BigKNY3 who wrote (6749)	1/20/1999 7:55:00 AM
From: Anthony Wong	Read Replies (1) \| Respond to of 9523

More analyst reaction from this Reuters update: biz.yahoo.com Neil Sweig, an analyst for Southeast Research Partners, said Viagra's fourth-quarter sales were about $70 million less than his own forecast. But he added that a surprisingly strong showing for three other key Pfizer drugs made up for that disappointment. Antibiotic Zithromax's sales rose 42 percent to $379 million, while antidepressant Zoloft was 24 percent to $489 million and antifungal drug Diflucan rose 9 percent to $248 million.